Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Neuroendocrine Carcinomas (NEC) Clear all

Recruiting Phase 1Phase 2 Interventional

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

NCT07174583

View directory record Official record

Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
Interventions: IDE849, durvalumab, IDE161; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older

Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Denver, Colorado • Jacksonville, Florida • Orlando, Florida + 14 more

Source: ClinicalTrials.gov public record

Updated Jan 22, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

NCT06132113

View directory record Official record

Conditions: Neuroendocrine Neoplasms
Interventions: BI 764532, Carboplatin, Etoposide, Cisplatin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

NCT02955069

View directory record Official record

Conditions: Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions: PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated Apr 11, 2021 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727

View directory record Official record

Conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions: 225Ac-ETN029, 111In-ETN029; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years

Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more

Source: ClinicalTrials.gov public record

Updated May 4, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521

View directory record Official record

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions: MT-4561; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 10, 2025 · Synced May 21, 2026, 10:12 PM EDT

Completed Phase 2 Interventional Results available

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

NCT03136055

View directory record Official record

Conditions: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Interventions: Pembrolizumab, Irinotecan, Paclitaxel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • New York, New York

Source: ClinicalTrials.gov public record

Updated Dec 26, 2022 · Synced May 21, 2026, 10:12 PM EDT

Active, not recruiting Phase 2 Interventional

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

NCT04701307

View directory record Official record

Conditions: Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions: Dostarlimab, Niraparib; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 21, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686

View directory record Official record

Conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Interventions: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Duarte, California • Denver, Colorado • Baltimore, Maryland + 8 more

Source: ClinicalTrials.gov public record

Updated Sep 22, 2025 · Synced May 21, 2026, 10:12 PM EDT

Not yet recruiting Phase 1 Interventional

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

NCT07488923

View directory record Official record

Conditions: Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Interventions: ML261; Biological
Lead sponsor: Moonlight Bio, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Hackensack, New Jersey • New York, New York • Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Apr 28, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 2 Interventional

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

NCT06406465

View directory record Official record

Conditions: Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell; Receptors
Interventions: Belinostat, Cisplatin, Etoposide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 21, 2026, 10:12 PM EDT

Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

NCT04514497

View directory record Official record

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1Phase 2 Interventional

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479

View directory record Official record

Conditions: Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
Interventions: [212Pb]Pb-MP0712, [203Pb]Pb-MP0712; Drug · Other
Lead sponsor: Molecular Partners AG; Industry
Eligibility: 18 Years and older

Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Glen Burnie, Maryland • Omaha, Nebraska • Princeton, New Jersey

Source: ClinicalTrials.gov public record

Updated Apr 7, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

NCT07129252

View directory record Official record

Conditions: SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Interventions: CRN09682; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Phoenix, Arizona • Duarte, California • Newport Beach, California + 17 more

Source: ClinicalTrials.gov public record

Updated May 10, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 2 Interventional

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146

View directory record Official record

Conditions: Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Gastric Cancer, Cholangiocarcinoma, Bladder Cancer
Interventions: [18F]FAPI-74, [18F]FDG; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years

Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 10:12 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

NCT03647163

View directory record Official record

Conditions: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Source: ClinicalTrials.gov public record

Updated Sep 15, 2025 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

NCT06889493

View directory record Official record

Conditions: Neuroendocrine Carcinoma, Neuroendocrine Tumors
Interventions: Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab; Biological · Drug
Lead sponsor: Peter Hosein, MD; Other
Eligibility: 18 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 2Phase 3 Interventional

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

NCT05058651

View directory record Official record

Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 244
States / cities: Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 188 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 21, 2026, 10:12 PM EDT